147 related articles for article (PubMed ID: 31414399)
1. Neuroendocrine Cancer of the Prostate.
Kránitz N; Szepesváry Z; Kocsis K; Kullmann T
Pathol Oncol Res; 2020 Jul; 26(3):1447-1450. PubMed ID: 31414399
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
Metzger AL; Abel S; Wegner RE; Fuhrer R; Mao S; Miller R; Beriwal S; Horne ZD
Prostate; 2019 Sep; 79(12):1457-1461. PubMed ID: 31294484
[TBL] [Abstract][Full Text] [Related]
3. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine cancer of the prostate. A series of 6 cases].
Breton X; Plazanet C; Murat FJ; Milinkevitch S; Irani J; Levillain P; Doré B
Prog Urol; 2003 Dec; 13(6):1340-4. PubMed ID: 15000310
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer.
Aparicio A; Tzelepi V
Oncology (Williston Park); 2014 Oct; 28(10):831-8. PubMed ID: 25323607
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
10. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
[TBL] [Abstract][Full Text] [Related]
11. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy.
Shimizu S; Kumagai J; Eishi Y; Uehara T; Kawakami S; Takizawa T; Koike M
Prostate; 2007 May; 67(6):645-52. PubMed ID: 17342745
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
16. Reprint of: de novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Xu X; Huang YH; Li YJ; Cohen A; Li Z; Squires J; Zhang W; Chen XF; Zhang M; Huang JT
Asian J Androl; 2017; 19(6):686-693. PubMed ID: 27905327
[TBL] [Abstract][Full Text] [Related]
18. Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.
Adwan R; Prošvic P; Prošvicová J; Tomšová M
Rozhl Chir; 2018; 97(9):427-431. PubMed ID: 30470124
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrine tumor of the prostate. A case report].
Zannoud M; Ghadouane M; Kasmaoui H; Alami M; Jira H; Ouhbi Y; Albouzidi A; Abbar M
Ann Urol (Paris); 2002 Jan; 36(1):58-61. PubMed ID: 11859580
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine prostate cancer].
Kretschmer A; Wittekind C; Stief CG; Gratzke C
Urologe A; 2015 Dec; 54(12):1779-83. PubMed ID: 26582381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
